Hyperthyroid Fetal Goiter: A Case Report

Vedi Loue; Mamadou Traore; Charles Kacou; Arthur Kouame; Eleonore Gbary-Lagaud; Julie Grevoul-Fesquet

doi:doi:10.11648/j.jgo.20190703.14

| Peer-Reviewed

Hyperthyroid Fetal Goiter: A Case Report

Vedi Loue, Mamadou Traore, Charles Kacou, Arthur Kouame, Eleonore Gbary-Lagaud, Julie Grevoul-Fesquet

Published in Journal of Gynecology and Obstetrics (Volume 7, Issue 3)

Received: 5 December 2018 Accepted: 1 February 2019 Published: 11 June 2019

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The persistent presence of maternal thyroid-stimulating hormone receptor antibody in patients with Graves’disease could cause fetal hyperthyroid goiter during pregnancy. The recognition and treatment of hyperthyroid fetal goiter are believed to be very important to optimize growth and intellectual development in affected fetuses. We report here, a case of a hyperthyroid fetal goiter identified by ultrasound exam at 27 weeks 5 days of gestation in a women having Graves’ disease and on antithyroid drugs therapy. This observation shows the fetal risk associated with the persistence of anti-TSH receptor antibodies in mothers with Graves' disease and the possibility of fetal approach.

Published in	Journal of Gynecology and Obstetrics (Volume 7, Issue 3)
DOI	10.11648/j.jgo.20190703.14
Page(s)	76-80
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Graves’ Disease, Thyroid Hormones, Fetal Hyperthyroid Goiter, Prenatal Diagnosis

References

[1]	Aynadis Alemu, Betelihem Terefe, Molla Abebe, Belete Biadgo. Thyroid hormone dysfunction during pregnancy: A review. Int J Reprod BioMed 2016; 14, 11: 677-86.
[2]	Kazakou P,Theodora M, Kanaka-Gantenbein C,et al. Fetal hyperthyroidism associated with maternal thyroid autoantibodies: A case report. Case Reports in Women's Health 2018; 19: e00081.
[3]	Andersen SL, Laurberg P. Managing hyperthyroidism in pregnancy: current perspectives. International Journal of Women’s Health 2016: 8 497-504.
[4]	Kurtoğlu S, Özdemir A. Fetal neonatal hyperthyroidism: diagnostic and therapeutic approachment. Turk Pediatri Ars 2017; 52: 1-9.
[5]	De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016; 388 (10047): 906-918.
[6]	Nguyen CT, Sasso EB, Barton L, Mestman JH. Graves’ hyperthyroidism in pregnancy: a clinical review. Clinical Diabetes and Endocrinology 2018; 4:4.
[7]	Bucci I, Giuliani C, Napolitano G. Thyroid-Stimulating Hormone Receptor Antibodies in Pregnancy: Clinical Relevance. Frontiers in Endocrinology 2017; 8: 137.
[8]	Banige M, Estellat C, Biran V, et al. Study of the Factors Leading to Fetal and Neonatal Dysthyroidism in Children of Patients With Graves Disease. Journal of the Endocrine Society 2017; 1,6: 751-61.
[9]	Léger J. Management of Fetal and Neonatal Graves' Disease. Horm Res Paediatr. 2017; 87 (1): 1-6.
[10]	Taff C. Prenatal diagnosis and treatment of fetal goiter. J Diagnosis Medical Sonography 2016; 32, 1: 40-3.
[11]	Neto JFG, Junior EA, Costa JIF, et al. Fetal goiter conservatively monitored during the prenatal period associated with maternal and neonatal euthyroid status. Obstet Gynecol Sci 2016; 59, 1: 54-7.
[12]	Mastrolia SA, Mandola A, Mazor M, et al. Prenatal diagnosis and treatment perspective of fetal hypothyroidism with goiter. J Matern Fetal Neonatal Med 2015; 28(18):2214-20.
[13]	Min-Jung Kim, Yong-Hwa Chae, So-Young Park, Moon-Young Kim. Intra-amniotic thyroxine to treat fetal goiter. Obstet Gynecol Sci 2016;59(1):66-70.
[14]	Song R, Lin H, Chen Y, Zhang X, Feng W. Effects of methimazole and propylthiouracil exposure during pregnancy on the risk of neonatal congenital malformations: A metaanalysis. PloS ONE 2017; 12(7): e0180108.

Cite This Article

Plain Text BibTeX RIS

APA Style

Vedi Loue, Mamadou Traore, Charles Kacou, Arthur Kouame, Eleonore Gbary-Lagaud, et al. (2019). Hyperthyroid Fetal Goiter: A Case Report. Journal of Gynecology and Obstetrics, 7(3), 76-80. https://doi.org/10.11648/j.jgo.20190703.14

Copy | Download

ACS Style

Vedi Loue; Mamadou Traore; Charles Kacou; Arthur Kouame; Eleonore Gbary-Lagaud, et al. Hyperthyroid Fetal Goiter: A Case Report. J. Gynecol. Obstet. 2019, 7(3), 76-80. doi: 10.11648/j.jgo.20190703.14

Copy | Download

AMA Style

Vedi Loue, Mamadou Traore, Charles Kacou, Arthur Kouame, Eleonore Gbary-Lagaud, et al. Hyperthyroid Fetal Goiter: A Case Report. J Gynecol Obstet. 2019;7(3):76-80. doi: 10.11648/j.jgo.20190703.14

Copy | Download

@article{10.11648/j.jgo.20190703.14,
  author = {Vedi Loue and Mamadou Traore and Charles Kacou and Arthur Kouame and Eleonore Gbary-Lagaud and Julie Grevoul-Fesquet},
  title = {Hyperthyroid Fetal Goiter: A Case Report},
  journal = {Journal of Gynecology and Obstetrics},
  volume = {7},
  number = {3},
  pages = {76-80},
  doi = {10.11648/j.jgo.20190703.14},
  url = {https://doi.org/10.11648/j.jgo.20190703.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20190703.14},
  abstract = {The persistent presence of maternal thyroid-stimulating hormone receptor antibody in patients with Graves’disease could cause fetal hyperthyroid goiter during pregnancy. The recognition and treatment of hyperthyroid fetal goiter are believed to be very important to optimize growth and intellectual development in affected fetuses. We report here, a case of a hyperthyroid fetal goiter identified by ultrasound exam at 27 weeks 5 days of gestation in a women having Graves’ disease and on antithyroid drugs therapy. This observation shows the fetal risk associated with the persistence of anti-TSH receptor antibodies in mothers with Graves' disease and the possibility of fetal approach.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - Hyperthyroid Fetal Goiter: A Case Report
AU  - Vedi Loue
AU  - Mamadou Traore
AU  - Charles Kacou
AU  - Arthur Kouame
AU  - Eleonore Gbary-Lagaud
AU  - Julie Grevoul-Fesquet
Y1  - 2019/06/11
PY  - 2019
N1  - https://doi.org/10.11648/j.jgo.20190703.14
DO  - 10.11648/j.jgo.20190703.14
T2  - Journal of Gynecology and Obstetrics
JF  - Journal of Gynecology and Obstetrics
JO  - Journal of Gynecology and Obstetrics
SP  - 76
EP  - 80
PB  - Science Publishing Group
SN  - 2376-7820
UR  - https://doi.org/10.11648/j.jgo.20190703.14
AB  - The persistent presence of maternal thyroid-stimulating hormone receptor antibody in patients with Graves’disease could cause fetal hyperthyroid goiter during pregnancy. The recognition and treatment of hyperthyroid fetal goiter are believed to be very important to optimize growth and intellectual development in affected fetuses. We report here, a case of a hyperthyroid fetal goiter identified by ultrasound exam at 27 weeks 5 days of gestation in a women having Graves’ disease and on antithyroid drugs therapy. This observation shows the fetal risk associated with the persistence of anti-TSH receptor antibodies in mothers with Graves' disease and the possibility of fetal approach.
VL  - 7
IS  - 3
ER  -

Copy | Download

Author Information

Vedi Loue

Sud Francilien Hospital Center (Woman-Mother-Child Pole), Paris Descartes University, Paris, France; Faculty of Medical Sciences (Mother and Child Department, University Hospital of Cocody), Felix Houphouet-Boigny University, Abidjan, Cote d’Ivoire
Mamadou Traore

Sud Francilien Hospital Center (Woman-Mother-Child Pole), Paris Descartes University, Paris, France
Charles Kacou

Faculty of Medical Sciences (Mother and Child Department, University Hospital of Cocody), Felix Houphouet-Boigny University, Abidjan, Cote d’Ivoire
Arthur Kouame

Faculty of Medical Sciences (Mother and Child Department, University Hospital of Cocody), Felix Houphouet-Boigny University, Abidjan, Cote d’Ivoire
Eleonore Gbary-Lagaud

Faculty of Medical Sciences (Mother and Child Department, University Hospital of Cocody), Felix Houphouet-Boigny University, Abidjan, Cote d’Ivoire
Julie Grevoul-Fesquet

Sud Francilien Hospital Center (Woman-Mother-Child Pole), Paris Descartes University, Paris, France

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Vedi Loue, Mamadou Traore, Charles Kacou, Arthur Kouame, Eleonore Gbary-Lagaud, et al. (2019). Hyperthyroid Fetal Goiter: A Case Report. Journal of Gynecology and Obstetrics, 7(3), 76-80. https://doi.org/10.11648/j.jgo.20190703.14

Copy | Download

ACS Style

Vedi Loue; Mamadou Traore; Charles Kacou; Arthur Kouame; Eleonore Gbary-Lagaud, et al. Hyperthyroid Fetal Goiter: A Case Report. J. Gynecol. Obstet. 2019, 7(3), 76-80. doi: 10.11648/j.jgo.20190703.14

Copy | Download

AMA Style

Vedi Loue, Mamadou Traore, Charles Kacou, Arthur Kouame, Eleonore Gbary-Lagaud, et al. Hyperthyroid Fetal Goiter: A Case Report. J Gynecol Obstet. 2019;7(3):76-80. doi: 10.11648/j.jgo.20190703.14

Copy | Download

@article{10.11648/j.jgo.20190703.14,
  author = {Vedi Loue and Mamadou Traore and Charles Kacou and Arthur Kouame and Eleonore Gbary-Lagaud and Julie Grevoul-Fesquet},
  title = {Hyperthyroid Fetal Goiter: A Case Report},
  journal = {Journal of Gynecology and Obstetrics},
  volume = {7},
  number = {3},
  pages = {76-80},
  doi = {10.11648/j.jgo.20190703.14},
  url = {https://doi.org/10.11648/j.jgo.20190703.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20190703.14},
  abstract = {The persistent presence of maternal thyroid-stimulating hormone receptor antibody in patients with Graves’disease could cause fetal hyperthyroid goiter during pregnancy. The recognition and treatment of hyperthyroid fetal goiter are believed to be very important to optimize growth and intellectual development in affected fetuses. We report here, a case of a hyperthyroid fetal goiter identified by ultrasound exam at 27 weeks 5 days of gestation in a women having Graves’ disease and on antithyroid drugs therapy. This observation shows the fetal risk associated with the persistence of anti-TSH receptor antibodies in mothers with Graves' disease and the possibility of fetal approach.},
 year = {2019}
}

Copy | Download

TY  - JOUR
T1  - Hyperthyroid Fetal Goiter: A Case Report
AU  - Vedi Loue
AU  - Mamadou Traore
AU  - Charles Kacou
AU  - Arthur Kouame
AU  - Eleonore Gbary-Lagaud
AU  - Julie Grevoul-Fesquet
Y1  - 2019/06/11
PY  - 2019
N1  - https://doi.org/10.11648/j.jgo.20190703.14
DO  - 10.11648/j.jgo.20190703.14
T2  - Journal of Gynecology and Obstetrics
JF  - Journal of Gynecology and Obstetrics
JO  - Journal of Gynecology and Obstetrics
SP  - 76
EP  - 80
PB  - Science Publishing Group
SN  - 2376-7820
UR  - https://doi.org/10.11648/j.jgo.20190703.14
AB  - The persistent presence of maternal thyroid-stimulating hormone receptor antibody in patients with Graves’disease could cause fetal hyperthyroid goiter during pregnancy. The recognition and treatment of hyperthyroid fetal goiter are believed to be very important to optimize growth and intellectual development in affected fetuses. We report here, a case of a hyperthyroid fetal goiter identified by ultrasound exam at 27 weeks 5 days of gestation in a women having Graves’ disease and on antithyroid drugs therapy. This observation shows the fetal risk associated with the persistence of anti-TSH receptor antibodies in mothers with Graves' disease and the possibility of fetal approach.
VL  - 7
IS  - 3
ER  -

Copy | Download